• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Kite Pharma appoints Chris Nowers head of Europe Commercial Operations

Kite Pharma appoints Chris Nowers head of Europe Commercial Operations

October 24, 2016
CenterWatch Staff

Kite Pharma has announced the appointment of Chris Nowers as its head of Europe. Nowers will be based in London. In his new role, Nowers will oversee European commercial operations to build awareness in the region of Kite’s growing pipeline portfolio of chimeric antigen receptor (CAR) and T-cell receptor (TCR) therapy product candidates and prepare for the potential launch of the company’s lead product candidate, KTE-C19.

“The addition of Chris Nowers to our executive team will be instrumental to Kite as we expand our global footprint,” said Arie Belldegrun, M.D., FACS, chairman, president and chief executive officer of Kite. “The breadth of Chris’ commercial experience in global immuno-oncology is impressive, and makes him well-qualified to propel our pipeline of CAR-T and TCR therapy candidates to treat both blood-based and solid cancers into international markets.”

A seasoned executive with 30 years of commercial leadership experience in pharmaceutical, biotech and diagnostics companies, Nowers brings a track record of successfully driving differentiated strategies for product commercialization across therapeutic areas in a competitive global landscape.

“Kite is a truly innovative company at the cusp of transforming the paradigm of cancer treatment, and I am honored to play a role in bringing what could potentially be life-changing therapies to patients around the world,” said Nowers. “I look forward to working with such a dynamic and passionate team to advance our presence in Europe and continue our efforts in developing novel approaches in engineered cell therapy.”

Prior to joining Kite, Nowers held senior commercial leadership positions at Bristol-Myers Squibb, including head of Immuno-oncology and Hematology in France, where he led the successful launch of Opdivo (nivolumab), and as vice president of Global Commercialization for Yervoy (ipilimumab), where he led the global commercial launch. Previously, Nowers was vice president of Sales and Marketing at Genomic Health, and chief executive officer of Avantogen Oncology, a company developing early-stage cancer therapeutics. Nowers also served 11 years at Amgen in a variety of commercial leadership roles, including global commercial leader for Neurology and European director for Oncology and Hematology.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing